References
- Rondòn G, Saliba RM, Khouri I, et al. Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institutio analysis. Biol Blood Marrow Transplant 2008; 14: 859–866
- Larocca A, Piaggio G, Podestà M, et al. Boost of CD34 selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. Haematologica 2006; 91: 935–940.
- Kong Y, Chang YJ, Wang YZ, et al. Association of an impaired bone marrow microenvironment with secondary poor graft function after allogenic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013; 19: 1465–1473.
- Dominietto A, Raiola AM, Van Lint MT, et al. Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. Br J Haematol 2001; 112: 219–227.
- Remberger M, Watz E, Ringdén O, et al. Major ABO blood group mismatch increases the risk for graft failure after unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 675–682.
- Bacigalupo A, Socie’ G, Lanino E, et al. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party. Haematologica 2010; 95: 976–982.
- Sheppard D, Tay J, Bryant A, et al. Major ABO-incompatible BMT: isohemagglutinin reduction with plasma exchange is safe and avoids graft manipulation. Bone Marrow Transplant 2013; 48: 953–957.
- Bittencourt V, Rocha A, Filion I, et al. Granulocyte colony-stimulating factor for poor graft function after allogeneic stem cell transplantation: 3 days of G-CSF identifies long-term responders. Bone Marrow Transplant 2005; 36: 431–435.
- Lee J-W, Yoon S-S, Shen ZX, et al. Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. Blood 2010; 116: 2448–2454.
- Lee JW, Yoon SS, Shen ZX, et al. Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC study. Haematologica 2013; 98: 1045–1048
- Visani G, Guiducci B, Giardini C, et al. Deferasirox improves hematopoiesis after allogeneic hematopoietic SCT. Bone Marrow Transplant 2014; 49: 585–587.
- Vallejo C, Batlle M, Vázquez L, et al; Subcommittee of Non-Infectious Complications of the Grupo Español de Trasplante Hematopoyético (GETH). Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation. Haematologica 2014; 99: 1632–1637.
- Poon LM, Di Stasi A, Popat U, et al. Romiplostin for delayed platelet recovery and secondary thrombocitopenia following allogeneic stem cell transplantation. Am J Blood Res 2013; 3: 260–264.
- Stasia A, Ghiso A, Galaverna F, et al. CD34 selected cells for the treatment of poor graft function after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2014; 20: 1440–1443.
- Askaa B, Fischer-Nielsen A, Vindeløv L, et al. Treatment of poor graft function after allogeneic hematopoietic cell transplantation with a booster of CD34-selected cells infused without conditioning. Bone Marrow Transplant 2014; 49: 720–721.